Bluegrass Vascular Announces Decision by Medicare to Assign a New Technology Ambulatory Payment Classification (APC) for the Surfacer® System Procedure
- Bluegrass Vascular
SAN ANTONIO, Sept. 20, 2021 /PRNewswire/ — Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today that the Centers for Medicare & Medicaid Services (CMS) has finalized a new Healthcare Common Procedure Coding System (HCPCS) code and New Technology Ambulatory Payment Classification (APC) assignment for use of the Surfacer® Inside-Out® Access Catheter System (Surfacer System) procedure. Read more…
Related Reading
News / Coverage & Payment / Government & Legislative Affairs
AdvaMed Hosts Showcase on Capitol Hill, Urges Action on Reimbursement Pathway for AI-Enabled Medical Technology
July 26, 2024
This week, AdvaMed, the Medtech Association, hosted an Artificial Intelligence (AI) Demonstration Day event on Capitol Hill showcasing AI-enabled medical devices and technologies from leading health care companies. The event was honorarily co-hosted by Senators Martin Heinrich (D-NM) and Mike Rounds (R-SD), co-chairs of the Senate AI Caucus.
Event / Digital Health / Regulatory Affairs
AdvaMed Cybersecurity Summit
November 13, 2024
8:15 AM – 6:00 PM
Join us in Washington, D.C. for our Cybersecurity Summit that will address the future of medical device cybersecurity and changes in the industry landscape related to FDA requirements.
Resource / Regulatory Affairs
MedTech Reimbursement Playbook
July 17, 2024
Learn the basic principles of how medical technologies are covered and paid by insurers and the challenges medtech companies face.
News / Coverage & Payment
AdvaMed Praises CMS Draft Rule Improving Patient Access to Alzheimer’s, Cancer Diagnostics
July 11, 2024
Today, the Centers for Medicare and Medicaid Services (CMS) issued the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule for CY25, which includes significant wins for patients, including separate payments for diagnostic radiopharmaceuticals, which improves access and ensures better treatment and care. Also of note, CMS’s proposed rule includes coverage for CT Colonography, or virtual colonoscopy, an important tool in detecting colorectal cancer.
News / Coverage & Payment / Government & Legislative Affairs
House Committee Advances Bipartisan Bill to Expedite CMS Coverage of Breakthrough Medtech
June 27, 2024
The House Ways and Means Committee voted to pass the bipartisan H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act, during a markup meeting.
News / Coverage & Payment / Medical Imaging
AdvaMed Applauds Bipartisan Senate Letter Urging CMS to Establish a Reimbursement Pathway for AI-Enabled Medical Devices
June 13, 2024
This week, AdvaMed, the Medtech Association, applauded a bipartisan group of Senators for urging the Centers for Medicare & Medicaid Services (CMS) to develop a formalized payment pathway for algorithm-based health care services (ABHS) in the upcoming Hospital Outpatient Prospective Payment Systems (HOPPS) rulemaking cycle. ABHS are FDA-cleared medical devices that rely on artificial intelligence (AI) and machine learning (ML) to produce clinical information to aid in patient diagnosis or treatment.
Resource / Regulatory Affairs
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
April 12, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
News / Coverage & Payment
AdvaMed to CMS: “1,138 Days Without Breakthrough Coverage is Harming Seniors”
April 11, 2024
AdvaMed, the Medtech Association, unveiled a timer on the organization’s website to track the number of days since the Centers for Medicare and Medicaid Services (CMS) ended the coverage pathway for FDA-approved breakthrough medical devices.